Triple antiplatelet therapy (TAPT, or triple therapy), is an oral medication regimen designed to reduce the risk of major cardiovascular events. It consists of aspirin, clopidogrel or an alternative, and an oral anticoagulant (OAC). It differs from dual antiplatelet therapy (DAPT) due to inclusion of an OAC. Multiple clinical studies have indicated that triple therapy is more effective at clot prevention, when compared to aspirin monotherapy and DAPT, but is associated with a higher risk of major bleeding. Pharmacists have a key role in determining candidates for DAPT and TAPT regimens. Other opportunities for pharmacists include patient monitoring, counseling and medication review throughout treatment with antithrombotic therapy.
Cwikla IE, Horvath KC, Gollmar E, Hilverding A, Petersen E. Triple Therapy or Triple Threat: An Analysis of Triple Antiplatelet Therapy Compared to Dual Antiplatelet Therapy. PAW Review. 2017 Jan 01; 8(1):Article 3 13-16 . Available from: https://digitalcommons.onu.edu/paw_review/vol8/iss1/3.